To demonstrate the rationality of the Grad-CAM explanation, lapatinib, a highly selective [42] EGFR/HER2 targeting dual inhibitor used in the treatment of breast cancer [43, 44], was introduced and explained by the EGFR model (Fig. 2). Here, EGFR is linked to breast cancer.